Inotek Pharmaceuticals Corporation (ITEK)
(Real Time Quote from BATS)
$3.04 USD
-0.16 (-5.00%)
Updated Jan 4, 2018 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Rocket Pharmaceuticals, Inc. [ITEK]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are terminating coverage due to the departure from the firm of the covering analyst
Provider: H.C. Wainwright & Co., Inc.
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Final Strikeout in Glaucoma Leaves Inotek Looking for New Players; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage of ITEK shares to reallocate our research resources
Provider: Roth Capital Partners, Inc.
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDC Data Nearly Ready; Monotherapy Is on Back-Burner
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Completed Enrollment in FDC Clarifies Key Event Timeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Inotek All-In on FDC Phase 2 Data Expected Mid-2017
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MATrX-1 Disappoints; Nevertheless, We Remain Optimistic on Trabo''s Future
Provider: Roth Capital Partners, Inc.
Analyst: YANIV S
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Giving Red Eye a Black Eye: Initiating with Buy and $10 PT
Provider: Roth Capital Partners, Inc.
Analyst: YANIV S
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rocket Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating with a Buy and $22 target.
Provider: H.C. Wainwright & Co., Inc.
|